There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan-oral direct-acting antiviral agents (DAAs). We performed a systematic review and meta-analysis to compare the rate of HBV reactivation in CHC patients coinfected with overt HBV (hepatitis B surface antigen [HBsAg] positive) and occult HBV (HBsAg negative with positive HBV DNA) infection separately, treated with interferon (IFN)-based therapy to those with pan-oral DAAs. The primary outcome was HBV reactivation, and the secondary outcomes included hepatitis due to HBV reactivation, sustained virologic response (SVR) for CHC, loss of HBV DNA and HBsAg seroclearance. Although the pooled incidence rate of HBV reactivation, among CHC patients with overt HBV (n 5 779), was similar among those treated with IFN-based therapy (14.5%, P < 0.001) and DAAs (12.2%, P 5 0.03; P 5 0.91 for heterogeneity between subgroups), it was reported to occur much earlier in those treated with DAAs (4-12 weeks during treatment) than in those treated with IFN-based therapies (most at the end of treatment and some during follow-up). Also, studies with DAA-based therapies were more likely to report incidence of hepatitis due to HBV reactivation (12.2% in DAAs vs. 0% in IFN; P 5 0.009 for heterogeneity between subgroups). HBV reactivation and hepatitis due to HBV reactivation also occurred, though less frequently in CHC patients with occult HBV infection. CHC SVR was not affected by HBV reactivation (P 5 0.27). Conclusion: HBV reactivation occurs earlier and is clinically more significant in CHC patients coinfected with overt and occult HBV who are treated with pan-oral DAAs compared with IFN-based therapy. It is therefore important to have all patients screened for evidence of overt or occult HBV infection and managed during pan-oral DAAs therapy. (HEPATOLOGY 2017;66:13-26).
where HBV infection is endemic, HBV and HCV coinfection has been estimated to be as high as 8.4%. (3) Similar to patients coinfected with HBV and HCV treated with interferon (IFN)-based therapy, hepatitis due to HBV reactivation in chronic hepatitis C (CHC) patients coinfected with HBV has also been reported after treatment with pan-oral direct-acting antiviral agents (DAAs). (4) (5) (6) (7) (8) The severity of hepatitis ranged from HBV reactivation without hepatitis (4) to fulminant hepatic failure, requiring liver transplantation. (5) The occurrence of these events had recently prompted both the US Food and Drug Administration and the European Medicine Agency's Pharmacoviglance Risk Assessment Committee to confirm the risk of HBV reactivation after DAA therapy. (9, 10) In keeping with this, recommendations have been made by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) (11) and European Association for the Study of the Liver (EASL) (12) to screen all CHC patients before DAA therapy for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody, and hepatitis B core antibody. However, whether serum or plasma HBV DNA measurement is necessary and how HBV-infected CHC patients should be managed remain unclear. (9, 11) So far, there are only very limited clinical trial data available for DAA treatment of HBV/HCV-coinfected patients. The objective of this systematic review and meta-analysis was to provide an updated estimate of the efficacy and safety of anti-HCV treatment (IFN-based therapy vs. IFN-free pan-oral DAAs) in CHC patients coinfected with HBV (overt vs. occult). This will help facilitate a better understanding of the potential risk of HBV reactivation in HCV/HBV-coinfected patients treated with DAAs, which is of importance with regard to the formulation of management guidelines.
Methods

LITERATURE SEARCH
The data retrieved for the systematic review was based on published studies that examined the efficacy and safety of antiviral therapies in HBV/HCVcoinfected patients. Figure 1 presents a schematic diagram of the literature search process, including inclusion and exclusion criteria. The PubMed, Embase, Ovid Medline, and Cochrane databases were searched by text and MeSH terms (including all subheadings) from database inception to September 21, 2016, using the terms hepatitis B virus and hepatitis C virus coinfect*, hepatitis B virus and hepatitis C virus coinfect*, hepatitis B virus and hepatitis C virus dual infect*, HBV and HCV coinfect*, HBV and HCV coinfect*, HBV and HCV dual infect*, HBV/HCV coinfect*, HBV/HCV coinfect*, and HBV/HCV dual infect* (Supporting Information). No language or study type (e.g., case-control, cohort) was limited. Three authors (G.F.C., C.W., and J.C.) independently screened titles and abstracts to identify relevant studies. Differences between screeners were discussed and reconciled. References of identified review articles were manually searched for additional relevant articles. Conference proceedings and abstract books were also searched. When more than one study from the same study population was available, the study with the most comprehensive data was used. We adhered to systematic review and meta-analysis methodology consistent with the PRISMA statement, and our protocol was registered on PROSPERO (registration number: CRD42016046760). 
ARTICLE INFORMATION:
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria for the systematic review were as follows: studies conducted in HBV/HCV coinfected population; studies used anti-HCV treatment; studies reported at least one clinical outcome of anti-HCV treatment (e.g., sustained virologic response [SVR] ). Patient populations were excluded if they featured coinfection with hepatitis A, D, or E virus or human immunodeficiency virus or concomitant use of anti-HCV drugs and anti-HBV nucleot(s)ide analogues (NUCs). Any dataset for which sufficient analytic information was not available was also excluded from the meta-analysis.
ENDPOINTS OF INTEREST
The primary endpoint was HBV reactivation as defined by the authors. The definition varied across studies: an increase of HBV DNA was defined as greater than two logs elevation of serum HBV DNA from the baseline level on at least one occasion (8, 13, 14) ; an increase of HBV DNA to >4 log 10 copies/mL during and off treatment (15) ; an elevation of serum HBV DNA >1000 copies/mL at the end of therapy or thereafter (16) ; an increase of HBV DNA to >2000 IU/ mL (17) ; and reappearance of HBV DNA. (4, 5, 8, (18) (19) (20) The rest of the studies stated the phenomenon without clear definition. (7, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) The secondary endpoint was the occurrence of hepatitis due to HBV reactivation as defined by the authors. The definition was not consistent across studies, with different levels of alanine aminotransferase (ALT) being used, including at least three times the upper limit of normal, (19) >10 times the upper limit of normal, (15, 31) and a more than twofold increase of serum ALT on two consecutive determinations at least 5 days apart, between the nadir during DAA therapy and follow-up (8) ; furthermore, many studies only stated whether HBV reactivation resulted in hepatitis (13, 14, 16, 17, 20, 22, 28, 29) or ALT flare-up. (25) (26) (27) Other secondary endpoints included HCV SVR for 24 or 12 weeks posttreatment, loss of HBV DNA, HBsAg seroclearance, and HBsAg seroconversion. All endpoints were assessed according to the definitions established by the authors.
DATA EXTRACTION
Data were extracted independently by two authors (C.W. and J.C.). Extracted information included study type, study year(s), study population characteristics, location of data collection, number of patients included, number of patients treated with anti-HCV therapy, type of anti-HCV treatment, duration of anti-HCV treatment, baseline HBV markers and HBV DNA status, and outcome measures as defined above. Disagreements were resolved by discussion with a third author (C.G.F.).
QUALITY ASSESSMENT
We used the study quality assessment tools from the US National Institutes of Health to assess study quality (https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools). The studies were rated as good, fair, and poor against the tools correspondent to each study type. In general, a good study had the least risk of bias, and the results were considered to be valid. A fair study was susceptible to some bias deemed insufficient to invalidate its results. A poor rating indicated significant risk of bias. Study quality was assessed independently by two authors (C.W. and J.C.), and disagreements were resolved by discussion with a third author (C.G.F.).
ANALYSIS
The rate of HBV reactivation and hepatitis due to HBV reactivation were calculated as the number of patients with HBV reactivation (as defined by the authors) or number of patients with hepatitis due to HBV reactivation (as defined by the authors) divided by the number of patients treated with anti-HCV treatment. HCV SVR was calculated as the number of patients with SVR 24 or 12 divided by the number of patients treated with anti-HCV treatment. We hypothesized that the baseline level of HBV replication would have an impact on the HBV reactivation. Thus, we performed the analysis separately in anti-HCVpositive patients coinfected with overt HBV (HBsAgpositive) and coinfected with occult HBV (HBsAgnegative with positive HBV DNA). The Stata software command metaprop was used with a random effects model to compute the pooled estimates of proportions of each endpoint, stratified by type of anti-HCV treatment (i.e., IFN-based and IFN-free DAAs). Studies with proportions equal to zero or 100% were also included. Score statistics and the exact binomial method was used to compute the 95% confidence intervals and the Freeman-Tukey double arcisine transformation of proportions was incorporated to stabilize the variance of the raw proportions. Summary estimates of risk difference were obtained by using a random effects DerSimonian model to compare monoinfected and coinfected patients. Inverse variance weighting was used in pooled analysis. The I 2 statistic was used to estimate the percentage of variability across studies attributable to heterogeneity beyond chance, with 0%-40% considered to be low heterogeneity, 41%-60% moderate heterogeneity, 61%-80% substantial heterogeneity, and 81%-100% considerable heterogeneity. Publication bias was assessed using the Egger test and trim and fill analyses were used to adjust the effects for the presence of publication bias. The heterogeneity in estimates of the treatment effect attributable to baseline characteristics of the studies were explored by comparing summary results obtained from subsets of studies grouped by number of patients (1-30 vs. >30), ethnicity (Asian vs. non-Asian), age (<46 vs. 46), and treatment regimens (IFN-based therapy vs. IFNfree DAA therapy). A meta-regression was further conducted to identify sources of heterogeneity between subgroups in the estimates of the treatment effect by the above priori-specified potential sources. A twosided P value of less than 0.05 was regarded as statistically significant. Stata version 13.0 (StataCorp, College Station, TX) was used for all statistical analysis. We used only previously published data, so approval from an ethics committee was not required.
Results
STUDY AND PATIENT CHARACTERISTICS
The search strategy identified 6224 records. After removing duplicates, the titles or abstracts of 3128 records were screened, and 84 publications as well as six additional publications from reference lists of screened publications were selected for full-text review (Fig. 1 ). This process yielded 36 studies, including 23 cohort studies, (8, (14) (15) (16) (17) 19, 20, 22, 23, (25) (26) (27) (28) (29) (32) (33) (34) (35) (36) (37) (38) (39) (40) of which four with matched control groups (16, 17, 20, 34) and six with comparable groups, (8, 27, 33, 36, 38, 39) one casecontrol study, (13) four trials, (21, 30, 31, 41) and eight case reports. (4) (5) (6) (7) 18, 24, 42, 43) These studies included 1185 HBV/HCV-coinfected patients with a mean age of 48 years (64% men; 36% Asian). Of the 36 studies, 29 (1037 coinfected patients) involved 24-48 weeks anti-HCV treatment with IFN-based therapy, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) and seven (148 coinfected patients) involved 8-12 weeks of treatment with DAAs (4) (5) (6) (7) (8) 29, 43) (Supporting Table S1 ); 27 (889 coinfected patients) were conducted in CHC patients coinfected with overt HBV (4, (6) (7) (8) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (28) (29) (30) (31) (32) 35, 36, (40) (41) (42) and nine (296 coinfected patients) were conducted in HCV patients coinfected with occult HBV. (5, 8, 27, 33, 34, (37) (38) (39) 43) Excluding eight case reports, 18 studies reported occurrence of HBV reactivation (779 overt HBV and 130 occult HBV coinfected patients), (8, (13) (14) (15) (16) (17) (19) (20) (21) (22) (23) (25) (26) (27) (28) (29) (30) (31) 15 studies reported the incidence of hepatitis (724 overt HBV and 130 occult HBV coinfected patients) due to HBV reactivation, (8, (13) (14) (15) (16) (17) 19, 20, 22, (25) (26) (27) (28) (29) 31) all 28 studies measured HCV SVR in coinfected patients (884 overt HBV and 292 occult HBV coinfected patients), and 11 studies compared HCV SVR in coinfected patients (497 overt HBV and 234 occult HBV coinfected patients) with HCV-monoinfected patients (2525 monoinfected patients). (8, 13, 16, 17, 20, 27, 33, 34, 36, 38, 39) 
QUALITY ASSESSMENT
Based on the assessment tools, all studies were rated as fair to good (Supporting Table S2 ). However, the sample size of the studies could be a potential risk of bias, because some of the studies had small sample size. The effect of sample size on the pooled effect size was tested.
HBV REACTIVATION
HBV reactivation was reported to occur much earlier in studies with IFN-free DAA-based therapies (mostly 4-12 weeks during the DAA treatment) than IFN-based therapies (most at the end of treatment and some during follow-up [Supporting Table S1] ). In CHC patients coinfected with overt HBV, metaanalysis revealed that the pooled HBV reactivation rate was 14.1% (95% confidence interval [CI], 7.6-22.0; P < 0.001) with evidence of heterogeneity in the size of effect across included studies (I 2 5 80%; P < 0.001; Fig. 2A ). The HBV reactivation rate estimated in studies with IFN-based therapy (14.5%; P < 0.001) was not different from IFN-free DAA-based therapy (12.2%; P 5 0.03; P 5 0.91 for heterogeneity between subgroups). Significant between-study heterogeneity was observed in studies by treatment regimen (P < 0.001 with I 2 exceeding 80% for both two treatment groups). No publication bias was presented (P 5 0.15). Univariable meta-regression of HBV reactivation according to the baseline characteristics revealed no evidence of heterogeneity between subgroups (all P > 0.05). In CHC patients coinfected with occult HBV, only one study (27) with IFN-based therapy reported the rate of HBV reactivation, which was zero. In contrast, HBV reactivation was recorded in three case reports in this group of patients who were treated with IFN-free DAAs (4, 5, 7) (Supporting Table S3 ). The HBV DNA of the coinfected patients treated with DAAs who experienced HBV reactivation varied from undetectable to 1.1 3 10 6 IU/mL, indicating that baseline HBV DNA was not associated with HBV reactivation during the treatment (Supporting Table S3 ).
HEPATITIS DUE TO HBV REACTIVATION
Studies with IFN-free DAAs-based therapies were more likely to report incidence of hepatitis as well as severe hepatitis [e.g., liver transplantation, (5) hepatic failure, (8, 43) icteric hepatitis (4, 8) ] due to HBV reactivation than those with IFN-based therapies. In CHC patients coinfected with overt HBV, the pooled incidence rate of hepatitis due to HBV reactivation was 0.0% (95% CI, 0-1.1; P 5 0.95) with some evidence of heterogeneity in the size of effect across included studies (I 2 5 44%; P 5 0.04; Fig. 2B ). The incidence rate was estimated to be 12.2% (95% CI, 0.2-33.2; P 5 0.03) in studies with DAA therapies, whereas it was 0% in studies with IFN-based therapies (P 5 0.009 for heterogeneity between subgroups). There was evidence of between-study heterogeneity among IFN-free DAA therapies (I 2 5 92%; P < 0.001), but not among studies with IFN plus ribavirin (I 2 5 7%; P 5 0.37). No 
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publication bias was presented (P 5 0.11) and there was no evidence of heterogeneity suggested across subgroups defined by the baseline characteristics (all P > 0.05). Only one study in CHC patients coinfected with occult HBV reported the rate of hepatitis due to HBV reactivation which was zero. (27) On the other hand, hepatitis due to HBV reactivation was recorded in case reports (5, 43) where IFN-free DAAs was used (Supporting Table  S3 ). Similar to HBV reactivation, with the big variation in baseline HBV DNA (undetectable to 1.1 310 6 IU/mL), baseline HBV DNA was not associated with hepatitis due to HBV reactivation during the treatment (Supporting Table S3 ). 
EFFICACY OF ANTI-HCV TREATMENT
In CHC patients coinfected with overt HBV, the pooled HCV SVR rate was 50.2% (95% CI, 37.1-63.2; P < 0.001), with evidence of heterogeneity in the size of effect across included studies (I 2 5 91%; P < 0.001; Fig. 3A ). Significant between-study heterogeneity was observed in studies with different treatment regimens (P < 0.001 with I 2 exceeding 90% for two treatment groups). There was also significant heterogeneity between subgroups (P < 0.001) and evidence of publication bias (P 5 0.04; Supporting Fig. S1 ) even with correction of the bias for the pooled estimation. Univariable meta-regression of HBV reactivation according to the baseline characteristics showed no evidence of heterogeneity between subgroups (all P > 0.05). HBV reactivation rate did not affect HCV SVR rate (P 5 0.27). In CHC patients coinfected with occult HBV, the pooled HCV SVR rate was 36.6% (95% CI, 1.8-82.2; P 5 0.02), with evidence of between-study heterogeneity in the size of effect across included studies (I 2 5 98%; P < 0.001; Fig. 3B ). There was no evidence of publication bias (P 5 0.17).
In CHC patients coinfected with overt HBV, the HCV SVR rate was 10.3% (95% CI, 0.2-20.4%; P 5 0.047) lower in coinfected patients compared with that in monoinfected patients, with some evidence of heterogeneity in the size of effect across included studies (I 2 5 80%; P 5 0.02; Fig. 4A ). No publication bias was presented (P 5 0.25). Univariable meta-regression of risk difference of HCV SVR showed that no baseline characteristics influenced the between-subgroups variation (all P > 0.05). In CHC patients coinfected with occult HBV, HCV SVR rate was not different in coinfected patients and in monoinfected patients (risk difference, 10.5%; 95% CI, 244.0%-23.1%; P 5 0.54; Fig. 4B ).
HBV SEROLOGIC AND VIROLOGIC RESPONSES
HBsAg seroclearance (n 5 12), HBsAg seroconversion (n 5 4), and HBV-DNA loss (n 5 16) were mainly reported in studies using IFN-based therapies. The pooled estimate of HBsAg seroclearance rate was 9.4% (95% CI, 3.1-17.8; P < 0.001; I 2 5 84%; P < 0.001), whereas the HBsAg seroconversion rate was 28.9% (95% CI, 9.7-52.3; P < 0.001; I 2 5 75%; P 5 0.007). The HBV-DNA loss rate was 51.7% (95% CI, 34.5-68.7) with evidence of between-study heterogeneity across included studies (I 2 5 83%; P < 0.001). Only one study (29) reported HBV serologic and virologic responses in coinfected patients treated with DAAs, and no HBsAg seroclearance was observed during treatment and quantification of HBsAg decreased during treatment. One case report using DAAs (4) recorded HBV DNA loss at the end of follow-up.
Discussion
In our study, we noted that there was more clinically significant hepatitis due to HBV reactivation in those treated with pan-oral DAAs than IFN-based therapy. Indeed, liver failure due to HBV reactivation resulting in the need for liver transplantation has been reported in patients treated with pan-oral DAAs. (8, 43) Another important feature of HBV reactivation in patients treated with pan-oral DAAs compared with IFNbased therapy is related to the timing of its occurrence. HBV reactivation was reported to occur much earlier in studies in which patients were treated with IFN-free DAA-based therapy (mostly 4-12 weeks during the treatment) than with IFN-based therapy (usually after the end of follow-up). Hence, HBV reactivation occurs not only much earlier but is generally more severe in patients treated with pan-oral DAAs compared with IFN-based therapy. What is the underlying mechanism of HBV reactivation and why is there clinical differences in terms of the timing and severity between interferon-based therapy and pan-oral DAAs? Previously, several reports have documented that de novo HCV superinfection in the setting of chronic hepatitis B can result in hepatitis B e antigen (HBeAg) seroconversion and in some cases, clearance of HBsAg. This suggested that HCV infection can suppress HBV replication.
(3) Hence, suppression or clearance of HCV infection with effective anti-HCV therapy with either IFN-or DAA-based therapy will remove the suppression on HBV replication and result in HBV reactivation. Recent cell culture studies further suggest that HCV suppresses HBV replication indirectly by way of IP-10-related innate immune mechanism. (44) In contrast to DAAs, IFN also exerts an inhibitory effect on HBV replication. (45) This additional inhibitory effect of IFN on HBV probably ameliorates HBV reactivation and delays its occurrence, because it took some time for the IFN effect to wane after stopping therapy. Whether there is any additional role of hepatotoxicity for DAAs versus IFN warrants further exploration.
In the most updated AASLD/EASL guidelines and US Food and Drug Administration box warnings, testing of HBV status before starting DAAs for HCV is recommended. However, the need for further serum and plasma HBV DNA testing remains controversial. (46) Our review shows that a few CHC patients with coinfected HBV who had undetectable or very low baseline HBV DNA experienced HBV reactivation and hepatitis due to HBV reactivation. This finding suggests that the baseline HBV DNA level was not associated with HBV reactivation in CHC patients with either overt or occult HBV infection. Thus, it is not conclusive whether testing for HBV DNA serum or plasma before the start of DAA therapy would alter the management of CHC patients with either overt or occult HBV infection. (4, 5, 43) In addition, the cost to test for serum/plasma HBV DNA needs to be considered, especially in an HBV endemic area where overt or occult HBV infection is high. For instance, in China, it has been estimated that there are 10-30 million CHC patients, and among these, 4%-8% are HBsAg-positive (47) and up to 80% are hepatitis B core antibody-positive (personal communication). So far, all reports on HBV reactivation occurred in CHC patients with overt HBV were HBeAg-negative. In accordance to AASLD/IDSA guideline, initiation of anti-HBV NUC therapy should be undertaken in those with active HBV infection (i.e., HBV DNA >2000 IU/mL in chronic HBeAg-negative patients). In contrary, the EASL recommends concurrent anti-HBV NUC therapy in CHC patients with either overt or occult HBV infection. In our systemic review, patients with reactivation mostly could not fulfill the criteria to initiate treatment of chronic hepatitis B at baseline before the administration of DAA therapy according to the AASLD/IDSA recommendation because their baseline HBV DNA was low or undetectable before starting DAA therapy. Therefore, merely treating patients with baseline HBV DNA >2000 IU/mL will render many patients untreated, and as a result these patients will suffer from HBV reactivation during DAA therapy. This assertion is supported by a recent observational postmarketing study in which the majority of CHC patients with HBV reactivation had undetectable baseline serum HBV DNA and initiation of HBV treatment was delayed in seven of 16 (44%) patients, resulting in one death. (48) Whether preemptive anti-HBV NUC therapy is superior to deferred NUC therapy for patients with HBV reactivation detected by close monitoring, as in the scenario of HBV reactivation after chemotherapy, (49) remains to be determined. Large, wellcontrolled studies are needed to address this issue in the future.
In our study, we showed that HBV/HCV-coinfected patients had similar frequency of HBV reactivation, regardless of whether they were treated with IFN-based therapy or pan-oral DAAs. However, this figure should be considered with caution, because not all studies had HBV reactivation clearly defined, using the same standardized nomenclature as proposed by the AASLD [i.e., "reactivation of HBV replication should be defined as a marked increase in HBV replication (2 log increase from baseline levels or a new appearance of HBV DNA to a level of 100 IU/mL) in a person with previously stable or undetectable levels"]. (50) For instance, if this standard nomenclature had been applied in the study by Gane et al., (29) three of the eight patients in that study would be regarded as having HBV reactivation. This finding would increase the HBV reactivation rate to 33.3% (P < 0.001) pooled from studies using IFN-free DAA-based therapy. In addition, in the case report by Hayashi et al., (43) there was no previous HBV replication status before HBV-related hepatitis, thus it is unclear whether the reported case was truly related to HBV reactivation. Hence, consensus on the definition is clearly needed to standardize the recording of HBV reactivation.
Another important question of great concern is whether the response to anti-HCV treatment is affected by HBV reactivation. Previous reports conflict on whether HCV SVR rates in HBV/HCV-coinfected patients are comparable to those of HCVmonoinfected patients who are treated with IFNbased therapy. (13, 17, 20, 27) In our meta-analysis, it was shown that HCV SVR was significantly lower by 10% in coinfected patients than in HCV-monoinfected patients who were treated with IFN-based therapy. This is unrelated to the occurrence of HBV reactivation, and the exact mechanism remains undetermined. Regarding DAAs, only one study compared HCV SVR between HBV/HCV-coinfected and HCVmonoinfected patients treated with IFN-free DAAbased therapy, and a comparable HCV SVR rate was found between the two groups. (8) Although the era of IFN-free DAA therapy promises a revolutionary change regarding the therapeutic options, it is at present inconclusive that HCV SVR rate is comparable between coinfected patients and monoinfected patients who are treated with IFN-free DAAs.
Finally, the effect of anti-HCV treatment on HBV virologic response (i.e., HBsAg seroclearance, HBsAg seroconversion, and HBV DNA loss) was observed in our meta-analysis as well. We found that in HBV and HCV coinfected patients treated with IFN-based therapy, the rate of HBsAg seroclearance was 9.4%, and HBV DNA loss was 52%. Baseline low pretreatment serum HBsAg level appeared to be correlated significantly with HBsAg seroclearance. However, in DAA-treated coinfected patients, HBsAg seroclearance was not reported. (4, 5, 7, 8) One of the main limitations of this review is the small number of studies using IFN-free DAA-based therapy yielding an important imbalance in groups subject to comparison, which would have allowed more reliable estimations of the effect and safety of IFN-free DAA-based therapy in coinfected patients. Additionally, the lack of individual participant data prevented assessment of the treatment effects in different patient groups (e.g., non-cirrhosis vs. cirrhosis).
In conclusion, hepatitis due to HBV reactivation occurs earlier and is clinically more significant in CHC patients who are coinfected with overt HBV compared with those with occult HBV when treated with panoral DAAs compared with IFN-based therapy. It is therefore important to have HBV serology (HBsAg and hepatitis B core antibody) screened in all CHC patients before initiation of pan-oral DAA therapy. Similar to HBV-infected patients who have undergone intense chemotherapy or transplantation, (49) the usefulness of preemptive administration of effective anti-HBV NUCs need to be further studied.
